Hexagon Nutrition IPO
Hexagon Nutrition IPO — date, price band, lot size & details 2026
Hexagon Nutrition listed on 12 Jun 2026 at ₹48.25, 7.2% above the ₹45 issue price.
Hexagon Nutrition is launching its IPO from June 5 to June 9, 2026, with a price band of ₹42 to ₹45 per share. Incorporated in 1993, the company is a research-driven nutrition and wellness player engaged in micronutrient premixes, clinical nutrition, therapeutic products, and ready-to-use foods. Hexagon Nutrition follows a B2B and B2C business model and has manufacturing units in Maharashtra, Tamil Nadu, and Uzbekistan, while exporting its products to over 70 countries globally.
Stock price
Hexagon Nutrition is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 10 October.
- Open 05 Jun 2026
- Close 09 Jun 2026
- Allotment 10 Jun 2026
- Refund/credit 11 Jun 2026
- Listing 12 Jun 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 5 to 9 Jun, 2026 |
|---|---|
| Price Band | ₹42 – ₹45 |
| Face Value | ₹1 |
| Lot Size | 333 Shares |
| Issue Size | ₹138.87 Cr |
| Sale Type | book build issue |
| Listing On | BSE, NSE |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 14,985 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 333 shares at the ₹45 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 333 | ₹14,985 |
| Retail (max) | 13 | 4,329 | ₹1,94,805 |
| S-HNI (min) | 14 | 4,662 | ₹2,09,790 |
| S-HNI (max) | 66 | 21,978 | ₹9,89,010 |
| B-HNI (min) | 67 | 22,311 | ₹10,03,995 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Strong presence in clinical nutrition and micronutrient premix segment.
- 02Exports products to over 70 countries across global markets.
- 03Diversified product portfolio reduces dependence on single category revenue.
- 04Experienced promoter family with long operational industry expertise.
- 05Focus on research-driven and affordable nutrition healthcare solutions.
Risks · 5
- 01Raw material price fluctuations may impact operating profit margins.
- 02High competition from established domestic and multinational nutrition companies.
- 03Business depends heavily on regulatory approvals and compliance standards.
- 04Export revenue exposure creates foreign currency fluctuation risks.
- 05Dependence on healthcare and nutrition demand trends for growth.
Three years of numbers
All figures in ₹ crore, as reported in the Hexagon Nutrition offer document.
| Metric | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 275.57 | 331.29 | 304.62 |
| EBITDA | 37.55 | 40.0724.88 | |
| Net Profit | 27.03 | 24.38 | 12.21 |
| Debt | 39.79 | 26.60 | 36.89 |
| Assets | 327.60 | 261.36 | 250.54 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Hexagon Nutrition RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Hexagon Nutrition IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹1.98 | ₹2.93 |
| P/E Ratio (x) | 22.69 | 15.35 |
| Market Cap at Offer Price (₹ Cr) | ₹553.00 | ₹653.80 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹45 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
How the company intends to use the proceeds of the issue.
About the company
The company offers a wide range of products including micronutrient premixes, vitamin and mineral blends, protein supplements, ready-to-use therapeutic foods, and clinical nutrition products. Hexagon Nutrition follows a diversified business model catering to both B2B and B2C segments, supplying nutritional ingredients to food and pharmaceutical companies while also selling branded healthcare products. Its strong research and development capabilities, export network across multiple countries, and focus on affordable nutrition solutions have helped the company expand its market presence globally.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
+91 22 6213 6710
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Cumulative Capital Pvt. Ltd.
3 issues handled (1 mainboard, 2 SME)Best listing: Goldline Pharmaceutical (+39.0%). Weakest: Veegaland Developers (+10.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Hexagon Nutrition?
The current Grey Market Premium is ₹2.75, or 6.1% over the issue price.
What is the Hexagon Nutrition IPO price band?
₹42 to ₹45, on a face value of ₹1.
When is the allotment?
The basis of allotment is 10 June 2026, with listing on 12 June 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
